Xenetic Biosciences Reports 36% Revenue Growth in Q1 2026, Net Loss Narrows

Xenetic Biosciences, Inc. reported its financial results for the first quarter of 2026, revealing a revenue increase of 36% year-over-year, reaching approximately $806,923 compared to $593,261 in the same period of 2025. This growth was primarily driven by higher royalty revenue from its sublicense agreement with Takeda Pharmaceuticals. Despite the increase in revenue, the company recorded a net loss of $456,382, a significant reduction from the $903,141 loss reported in the first quarter of 2025, indicating a 49.5% improvement in financial performance.

The company's operating costs and expenses also saw a decline, totaling $1,309,040 for the quarter, down 14.8% from $1,535,670 in the prior year. Research and development expenses decreased by 24.8% to $661,443, attributed to reduced costs in pre-clinical studies, while general and administrative expenses slightly decreased by 1.4% to $647,597. The overall reduction in expenses contributed to a narrower loss from operations, which fell to $502,117 from $942,409 in the previous year.

In terms of strategic developments, Xenetic has initiated a formal strategic review process to explore various alternatives aimed at maximizing shareholder value. This includes potential transactions such as the sale of the company or its assets, or a business combination. An independent committee of the board is currently engaged in discussions with third parties regarding these potential transactions, although no definitive agreements have been reached as of yet.

Operationally, the company maintained a cash balance of approximately $7.3 million as of March 31, 2026, down from $7.9 million at the end of 2025. Current liabilities remained stable at around $1 million. The company’s accumulated deficit increased slightly to $200.3 million, reflecting ongoing investments in its research and development initiatives. Xenetic continues to focus on advancing its proprietary DNase technology, which targets neutrophil extracellular traps in cancer treatment, particularly for pancreatic carcinoma and other solid tumors.

Looking ahead, Xenetic anticipates the need for additional capital to support its long-term business initiatives. The company believes it will have access to capital resources through various means, including public or private equity offerings and corporate collaborations. However, the timing and terms of any future financing will depend on several factors, including the progress of its product development programs and market conditions. The company remains committed to its strategic goals while navigating the uncertainties posed by geopolitical events and market volatility.